TRVI - Trevi stock rises on upcoming US patent for chronic cough drug Haduvio

2023-03-08 07:45:29 ET

• Trevi Therapeutics ( NASDAQ: TRVI ) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for its application covering the use of Haduvio (nalbuphine ER) to treat chronic cough in idiopathic pulmonary fibrosis (IPF).
• The company expects the patent will hold till 2039.
• "We are pleased with this allowance of claims to further secure IP protection for Haduvio through 2039 for the treatment of chronic cough in IPF," said Trevi President and CEO Jennifer Good. "We expect that this allowed patent application when issued will provide important protection along with the already issued formulation patents and other patent applications that we are prosecuting."
• IPF is a condition in which the lungs become scarred it gets difficult to breathe.
• TRVI +8% to $2.43 premarket March 8

For further details see: